readthroughSign in
Jul 17, 2026Weekly roundup

Merck completes MK-4082 obesity pill PK study; adds V132 vaccine and belzutifan pediatric trials

A completed oral obesity drug study and two newly listed trials join Merck's active Phase 3 DME and other ongoing registrations this week.

Merck Sharp & Dohme LLC posted seven active clinical trial records this week, including a newly completed early-stage study and two new registrations alongside its ongoing oncology, ophthalmology, and infectious disease trials.

  • A Phase 1 study of MK-4082, an oral candidate the company describes as a new weight loss medicine that differs from similar treatments by being taken as a pill instead of an injection1, has been marked completed (NCT07697625). The trial enrolled 28 participants1 and examined pharmacokinetics of MK-4082 alone and with diltiazem coadministration.
  • Two pivotal Phase 3 studies of MK-8748 (also known as EYE201 or Tiespectus) continue recruiting against aflibercept in diabetic macular edema. NCT07705555 plans to enroll 960 participants2, while NCT07705607 plans to enroll 1104 participants3.
  • A new Phase 1 study of V132, a vaccine candidate for healthy older adults, is recruiting (NCT07712575). The dose-escalation trial compares three V132 formulations against PREVNAR 20 and CAPVAXIVE, with enrollment estimated at 280 participants4.
  • A new Phase 2 substudy of belzutifan (also MK-6482, PT2977, WELIREG) under the LIGHTBEAM-U01 protocol is recruiting adolescents with solid tumors (NCT07700758). The study covers pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumor, and Von Hippel-Lindau disease-associated localized tumor cohorts5, with enrollment estimated at 15 participants.
  • MK-1045 (also CN201), a biological for chronic lymphocytic leukemia and small lymphocytic lymphoma, remains not yet recruiting in a Phase 2 study (NCT07709000) with enrollment estimated at 60 participants6.
  • A Phase 4 letermovir study for CMV prophylaxis in transplant recipients (NCT07706166) remains not yet recruiting; it is sponsored by the University of Wisconsin, Madison, with Merck as a collaborator, and enrollment is estimated at 146 participants7.
  • Merck remains a collaborator, with Daiichi Sankyo as lead sponsor, on the recruiting Phase 1b/2 HERTHENA-Breast02 trial combining patritumab deruxtecan with trastuzumab deruxtecan in HER2-low or HER2-ultralow breast cancer (NCT07701941), with enrollment estimated at 220 participants8.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.